(Q36292993)

13 August 2017

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS) (English)

1 reference

multicenter clinical trial

13 August 2017

0 references

1 reference

1 reference

Warner E

1

1 reference

13 August 2017

Goel R

2

1 reference

13 August 2017

Chang J

3

1 reference

13 August 2017

Chow W

4

1 reference

13 August 2017

Verma S

5

1 reference

13 August 2017

Dancey J

6

1 reference

13 August 2017

Franssen E

7

1 reference

13 August 2017

Dulude H

8

1 reference

13 August 2017

Girouard M

9

1 reference

13 August 2017

Correia J

10

1 reference

13 August 2017

Gallant G

11

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

12

1 reference

13 August 2017

2376-2380

1 reference

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Treatment of patients with cancer of an unknown primary site

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Empirical chemotherapy for adenocarcinoma of unknown primary tumor site

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Chronic daily administration of oral etoposide--a phase I trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Letter: Creatinine clearance: bedside estimate.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Phase II study of daily oral etoposide in refractory germ cell tumors

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150411

Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial

29 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9649162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9649162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Unknown primary tumours

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9649162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.1998.395

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

9649162

1 reference